title: Phosphodiesterase type 5 inhibitors and kidney disease.
abstract: Chronic kidney disease (CKD) represents a worldwide health problem. Traditionally, the nephroprotective treatment for CKD aims to slow progression to end-stage renal disease and includes dietary protein restriction, correction of metabolic acidosis, and renin-angiotensin system blockers. However, current standard therapeutic options may not be enough for preventing CKD progression in a subset of patients making necessary to develop novel therapeutic options to further slow renal function loss. Phosphodiesterase type 5 (PDE5) inhibitors represent a class of drugs traditionally used to treat erectile dysfunction and pulmonary hypertension. However, recent evidence suggests that PDE5 inhibitors may have additional therapeutic effects, such as cardioprotection and cerebrovascular protection. In the current review, we summarize PDE5 inhibitors' utility in disease states and clinical conditions related to kidney disease such as systemic hypertension and acute and chronic kidney injury and discuss the mechanisms explaining possible kidney protective roles of PDE5 inhibitors. A recently completed phase 2 trials demonstrated that the long-acting PDE5 inhibitor PF-00489791 decreased albuminuria in patients with overt diabetic nephropathy when added on top of renin-angiotensin system blockade.
authors.affiliation: Division of Nephrology, Department of Medicine, Konya Numune State Hospital, Konya, Turkey.
authors.forename: Baris
authors.initials: B
authors.lastname: Afsar
authors.forename: Alberto
authors.initials: A
authors.lastname: Ortiz
authors.forename: Adrian
authors.initials: A
authors.lastname: Covic
authors.forename: Abduzhappar
authors.initials: A
authors.lastname: Gaipov
authors.forename: Tarik
authors.initials: T
authors.lastname: Esen
authors.forename: David
authors.initials: D
authors.lastname: Goldsmith
authors.forename: Mehmet
authors.initials: M
authors.lastname: Kanbay
mesh_terms: D018450:Disease Progression; D006801:Humans; D058986:Phosphodiesterase 5 Inhibitors / Q000627:therapeutic use*; D051436:Renal Insufficiency, Chronic / Q000188:drug therapy* / Q000378:metabolism; D012084:Renin-Angiotensin System / Q000187:drug effects
chemical_list: D058986:Phosphodiesterase 5 Inhibitors